Maria Magdalena S. P.
- Country
- Spain
- Department
- Gastroenterology Hepatology
Research Overview
- Phase III Randomized Double‑Blind Placebo‑Controlled Study of Oral Elafibranor 120 mg in Adults with Primary Sclerosing Cholangitis
- Evaluation of Pharmacokinetics, Safety, and Efficacy of Golexanolone in Primary Biliary Cholangitis Patients with Fatigue and Cognitive Dysfunction
- Phase 3 Multicenter Double-Blind Randomized Placebo-Controlled Trial Evaluating Infigratinib Efficacy and Safety in Pediatric Achondroplasia Patients
Data & Insights
Has run more than one trial at 62 of 177 partner sites.
Specializations
Cholestatic Liver Diseases
The investigator specializes in treating Primary Biliary Cholangitis (PBC) and Primary Sclerosing Cholangitis (PSC), focusing on innovative therapeutic approaches for these chronic liver conditions.
- PBC Treatment Optimization
- PSC Management Strategies
- Cholestatic Disease Progression
Particular attention is given to managing complications such as cholestatic pruritus and liver function abnormalities.
Symptom Management
Expertise in addressing specific symptoms associated with liver diseases, particularly focusing on pruritus management in cholestatic conditions.
- Pruritus Treatment Innovation
- Quality of Life Improvement
- Symptom Assessment Methods
The investigator employs various therapeutic agents to address challenging symptoms in liver disease patients.
Transplant Medicine
Focused on advancing liver transplantation outcomes, with particular emphasis on preventing organ rejection through innovative therapeutic approaches.
- Transplant Rejection Prevention
- Novel Immunotherapy Applications
- Post-Transplant Care
Specializes in developing strategies for improving long-term outcomes in liver transplant recipients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.